SCHEMBL863528

SCHEMBL863528

C=CCOCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA9 Q16790 3/20 0.42
ALDH1A1 P00352 5/20 0.41
C5AR1 P21730 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
STAT3 P40763 1/20 0.38
TLR9 Q9NR96 1/20 0.38
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
GAA P10253 1/20 0.37
CYP24A1 Q07973 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
G6PD P11413 1/20 0.36
VDR P11473 1/20 0.36
CNR2 P34972 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8940473 0.98 ALDH1A1 (0.43) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL8940307 0.98 ALDH1A1 (0.43) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL30380565 0.98 ALDH1A1 (0.43) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL8875958 0.91 CYP24A1 (0.39) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL8672969 0.90 CYP24A1 (0.39) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL13913110 0.86 ALDH1A1 (0.43) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL26541640 0.86 ALDH1A1 (0.43) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL14562308 0.86 CA12 (0.43) CA12CA1CA9ALDH1A1STAT3
SCHEMBL169846 0.85 C5AR1 (0.44) CA12CA1CA9ALDH1A1C5AR1
SCHEMBL1145153 0.85 ALDH1A1 (0.53) CA12CA1CA9ALDH1A1STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105801603-A ALK inhibitor with macrocyclic structure and preparation method thereof 成都倍特药业有限公司 2016-07-27 CN claimed
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2026-02-26 US disclosed
US-20260034106-A1 Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics UNIV DARMSTADT TECH (DE) 2026-02-05 US disclosed
EP-4686495-A1 MACROCYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES WITH IMPROVED CHARACTERISTICS Technische Universität Darmstadt (DE) 2026-02-04 EP disclosed
US-20260028334-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2026-01-29 US disclosed
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-09-30 US disclosed
EP-4208466-B1 HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS UNIV DARMSTADT TECH (DE) 2025-06-11 EP disclosed
EP-4504723-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2025-02-12 EP disclosed
CN-118638043-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-09-13 CN disclosed
CN-118059104-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-05-24 CN disclosed
US-20120076755-A1 Hepatitis C Virus Inhibitors ENANTA PHARMACEUTICALS, INC. 2012-03-29 US disclosed
US-20110189129-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-08-04 US disclosed
WO-2011091417-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2011-07-28 WO disclosed
US-20100317850-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-16 US disclosed
CN-101910143-A Fused Aminodihydrothiazine Derivatives EISAI R&D MAN CO LTD 2010-12-08 CN disclosed
EP-2233474-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-09-29 EP disclosed
US-20090209755-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-20 US disclosed
US-20090082222-A1 PREPARATION OF SENSORS ON OLIGO- OR POLY (ETHYLENE GLYCOL) FILMS ON SILICON SURFACES UNIVERSITY OF HOUSTON (US) 2009-03-26 US disclosed
US-5693621-A INHIBITING BINDING OF SELECTIN TO CARBOHYDRATE LIGANDS HOECHST AKTIENGESELLSCHAFT (DE) 1997-12-02 US disclosed
US-5563230-A POLYETHERSILOXANES NATIONAL SCIENCE COUNCIL (TW) 1996-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, NR5A1, KLK3 CA12 254/4885CA1 691/4885CA9 26/4885
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 CA12 688/4885CA1 1904/4885CA9 325/4885
US-20090209755-A1 FUSED AMINODIHYDROTHIAZINE DERIVATIVES BACE1, APP, BACE2 CA12 3040/4885CA1 1040/4885CA9 4351/4885
US-20110189129-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, HCCS, NSUN2 CA12 3578/4885CA1 4360/4885CA9 3215/4885
US-20100317850-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE BACE1, APP, BACE2 CA12 2292/4885CA1 565/4885CA9 3700/4885
US-20260034106-A1 Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics FKBP3, FKBP2, FKBP1B CA12 3804/4885CA1 2988/4885CA9 4108/4885
US-20120076755-A1 Hepatitis C Virus Inhibitors NSUN2, HCCS, HAVCR2 CA12 3519/4885CA1 4390/4885CA9 3193/4885
US-20260028334-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER LDHA, LDHB, SLC6A1 CA12 1100/4885CA1 539/4885CA9 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.